7 news items
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
VKTX
4 Jun 24
compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative
Viking Therapeutics to Participate at Upcoming Investor Conferences
VKTX
30 May 24
of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
for the first quarter of 2024, compared with $8.5 million for the same period in 2023. Research and development expense was $6.0 million for the first
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
VKTX
24 Apr 24
by 7.14%.
Research and development expenses were $24.1 million for the first quarter, compared to $11 million for the same period in 2023
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
VKTX
24 Apr 24
Quarter 2024 Financial Highlights
Research and development expenses were
0w6rce kahk6c42477se9q1lhhdmo7ssgiq0kazack9ou89o55
VKTX
17 Apr 24
and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise
yv1aqar
VKTX
26 Mar 24
for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development
- Prev
- 1
- Next